Theoretically, they operate through different mechanisms: semaglutide suppresses appetite and slows gastric emptying via GLP-1 receptors, while AOD 9604 acts on beta-3 adrenergic receptors on fat cells
scar tissue formation at the injury site Anti-inflammatory down-regulates NF-B signaling, one of the key inflammatory pathways active in disc herniations Works in synergy with BPC-157 while BPC-157 creates the growth signals, TB-500 provides the cellular migration framework to execute the repair Protocol: Loading phase: 2.5mg5mg/week subcutaneous injection for 46 weeks Maintenance: 1.252.5mg/week ongoing Frequency: Single weekly injection or split into two 1.25mg injections across the week (both approaches work) The Synergy: Why Run Both Together BPC-157 and TB-500 work through different but complementary mechanisms
BPC-157 (10 ) + TB-500 (10 ) - BLEND: 1 = 33.3
And the reason I want to lay all that out is I'm not here to argue about the GLP1s
(Vukojevi et al., 2024) After his orthopedist left him with no direction, David did what many analytically minded people do when formal channels come up short: he started reading
, Potential Role for Stem Cell Regenerative Therapy as a Treatment for Degenerative Disc Disease and Low Back Pain: A Systematic Review, Int
